Boston Scientific Corporation (BSX)
| Market Cap | 61.27B |
| Revenue (ttm) | 10.12B |
| Net Income (ttm) | 201.00M |
| Shares Out | 1.42B |
| EPS (ttm) | 0.14 |
| PE Ratio | 307.06 |
| Forward PE | 27.55 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 10 |
| Last Price | $43.30 |
| Previous Close | $43.13 |
| Change ($) | 0.17 |
| Change (%) | 0.38% |
| Day's Open | 43.16 |
| Day's Range | 43.08 - 43.61 |
| Day's Volume | 4,375,387 |
| 52-Week Range | 32.99 - 44.63 |
Like most medical device manufacturers, Boston Scientific Corp. ( BSX , Financial) also witnessed a slowdown in 2020 on account of the lower demand for medical devices and the deferral of elective surge...
MARLBOROUGH, Mass., (May 3, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming investor conferences.
Rapid innovation is boosting the robotic surgery space, putting the spotlight on Johnson & Johnson (JNJ), Stryker (SYK), Boston Scientific (BSX), Intuitive Surgical (ISRG) and Asensus Surgical (ASXC).
Bulls bet on Boston Scientific and Las Vegas Sands
"Halftime Report" trader Pete Najarian spots unusual activity in the options market
Boston Scientific Corporation (NYSE: BSX) Q1 sales grew by 5.9% (organically) to $2.75 billion, beating the previous guidance range between negative 3% and 3% in the quarter, better than the consensus e...
Boston Scientific (BSX) registers strong sequential improvement in overall financial performance in Q1.
Boston Scientific (BSX) delivered earnings and revenue surprises of 23.33% and 5.30%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
MARLBOROUGH, Mass., April 28, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $2.752 billion during the first quarter of 2021.
Boston Scientific (BSX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Within Boston Scientific's (BSX) coronary therapies, drug-eluting stents sale continue to be a challenge from a pricing standpoint in Q1.
Boston Scientific (BSX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
EVP&Pres, Periph Intervent of Boston Scientific Corp (30-Year Financial, Insider Trades) Jeffrey B. Mirviss (insider trades) sold 28,123 shares of BSX on 04/15/2021 at an average price of $40.95 a share.
Final Trades: Northrop Grumman, Boston Scientific, Nvidia & more
The "Halftime Report" traders give their top picks to watch for the second half.
Boston Scientific's (BSX) TheraSphere is expected to be used as a safe and effective treatment option for numerous HCC patients worldwide on the back of positive trial results.
MARLBOROUGH, Mass., March 26, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the first quarter e...
Boston Scientific (BSX) currently expects its 2021 organic revenues to include a headwind of $62 million from 2020 LOTUS Edge sales.
MARLBOROUGH, Mass., March 25, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announced positive data from the TARGET study of the TheraSphere™ Y-90 Glass Microspheres (TheraSphere) – a t...
We think that Boston Scientific currently is a better pick compared to Illumina. BSX stock trades at about 5.6x trailing revenues, compared to around 18.8x for ILMN.
Boston Scientific's (BSX) TheraSphere therapy to be made accessible to more patients following the FDA's clearance.
MARLBOROUGH, Mass., March 18, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announced it has received U.S. Food and Drug Administration (FDA) approval of the TheraSphere™ Y-90 Glass Mic...
Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock?
The transaction is expected to remain immaterial to Boston Scientific's (BSX) 2021 adjusted earnings per share.
YOKNEAM, Israel and HONG KONG, March 3, 2021 /PRNewswire/ -- Baring Private Equity Asia (BPEA) and Lumenis announced today that they have entered into a definitive agreement to sell the Lumenis Surgical...
MARLBOROUGH, Mass., March 3, 2021 /PRNewswire/ -- Boston Scientific (NYSE: BSX) today announced that it has entered into a definitive agreement with an affiliate of Baring Private Equity Asia (BPEA) to ...
We think that Henry Schein currently is a better pick compared to Boston Scientific. HSIC stock trades at about 0.9x trailing Revenues, compared to around 5.5x for Boston Scientific.
Biotech stocks offer a textbook retracement pattern. The risk is low, and the reward is high.
MARLBOROUGH, Mass., Feb. 12, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming investor conferences. On February 25, 2021, Dan Brennan, executive vice presi...
Barring MedSurg, organic revenues at each of Boston Scientific (BSX) core segments and geographies are down in Q4 but the magnitude of this decline is lower than Q3.
Apart from a drop in Q4 earnings and revenues drop year over year, Boston Scientific (BSX) also registers strong sequential decline in overall financial performance.
Boston Scientific (BSX) delivered earnings and revenue surprises of -25.81% and -0.02%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Boston Scientific (NYSE:BSX) fell 2.0% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share decreased 50.00% year over year to $0.23, which missed ...
MARLBOROUGH, Mass., Feb. 3, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $2.708 billion during the fourth quarter of 2020. This represents a decline of (6.8) per...
New York, New York--(Newsfile Corp. - February 2, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of ...
LOS ANGELES--(BUSINESS WIRE)---- $BSX #BSX--DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against Boston Scientific Corporation
New York, New York--(Newsfile Corp. - February 2, 2021) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Boston Scientific Corporation (NYSE: BSX) between Apr...
New York, New York--(Newsfile Corp. - February 1, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Boston Scientific Corporation (NYSE: BSX)...
LOS ANGELES, Feb. 1, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Boston Scientific Corporation ("Bosto...
New York, New York--(Newsfile Corp. - February 1, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of B...
NEW YORK, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Boston Scientific Corporation...
NEW YORK, Feb. 1, 2021 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action...
NEW YORK, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Boston Scientific Corporation (NYSE: BSX) between April 24, 2019 an...
NEW YORK, Jan. 31, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Boston Scientific Corporation ("Boston Scientific" or the "Company") (NYSE: BSX) and ce...
New York, New York--(Newsfile Corp. - January 30, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Boston Scientific Corporation (NYSE: BSX) betwee...
New York, New York--(Newsfile Corp. - January 29, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of B...
About BSX
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and r... [Read more...]
| Industry Medical Devices | IPO Date May 18, 1992 |
| CEO Michael Mahoney | Employees 38,000 |
| Stock Exchange NYSE | Ticker Symbol BSX |
Analyst Forecasts
According to 27 analysts, the average rating for BSX stock is "Strong Buy." The 12-month stock price forecast is 49.04, which is an increase of 13.27% from the latest price.